Search

Search Constraints

You searched for: Author/Creator Ria, Roberto

Search Results

1. A multiple myeloma that progressed as type I cryoglobulinemia with skin ulcers and foot necrosis: A case report. Issue 39 (September 2018)

2. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. (9th November 2021)

3. Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. Issue 3 (4th March 2017)

4. Bone marrow endothelial cells sustain a tumor-specific CD8+ T cell subset with suppressive function in myeloma patients. (2nd January 2019)

5. CARDIOVASCULAR RISK SCORE MAY BE USEFUL IN STRATIFY DEATH RISK IN HOSPITALIZED COVID19 PATIENTS. (June 2022)

6. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Issue 16 (December 2015)

7. Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. (December 2018)

8. CORRELATION BETWEEN VASCULAR INFLAMMATION MARKERS, DIASTOLIC DYSFUNCTION AND CARDIOVASCULAR RISK IN PATIENTS WITH TAKAYASU ARTERITIS. (June 2022)

9. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials. Issue 4 (1st June 2022)

10. Evidence for Bone Marrow Adult Stem Cell Plasticity: Properties, Molecular Mechanisms, Negative Aspects, and Clinical Applications of Hematopoietic and Mesenchymal Stem Cells Transdifferentiation. (27th March 2013)